Skip to content

The effect of long-term Momordica Charantia supplementation on blood glucose levels

The effect of long-term Momordica Charantia supplementation on blood glucose levels - Bitter-Sweet 2 study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON51413
Enrollment
40
Registered
2022-01-11
Start date
2022-01-23
Completion date
Unknown
Last updated
2024-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

blood glucose pre-diabetes

Interventions

12-week intervention with 3.6 g/d dried bitter-gourd supplements or a reference intervention with 3.6 g/d dried cucumber supplements.

Sponsors

Wageningen Food and Biobased Research
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: • Age 40-75yrs • BMI >25 kg/m2 • Having a fasting glucose >= 5.6 mmol/L

Exclusion criteria

Exclusion criteria: • Use of medication/supplements that may influence the study results, such as metformin, gliclazide, glimepiride, tolbutamide, insulin, sitagliptin (DPP4 inhibitor), liraglutide (GLP-1 agonist), acarbose, repaglinide, pioglitazone, corticosteroids (systemically) , SGLT-2 inhibitors, (judged by our research physician) • Having a fasting glucose >11.0 mmol/L • History of gastro-intestinal surgery or having (serious) gastro-intestinal complaints • History of liver dysfunction (cirrhosis, hepatitis) or liver surgery • Kidney dysfunction (self-reported) • Reported slimming, medically prescribed or other extreme diets • Reported weight loss or weight gain of > 5 kg in the month prior to pre-study screening • Not willing to give up blood donation during the study • Current smokers • Alcohol intake >=14 glasses (women) or >21 glasses (men) of alcoholic beverages per week, on average • Not pregnant or lactating • Abuse of illicit drugs (soft- and hard drugs) • Food allergies for products that we use in the study • Participation in another clinical trial at the same time • Being an employee of the Food, Health & Consumer Research group of Wageningen Food & Biobased Research or dept. human nutrition and health of Wageningen University.

Design outcomes

Primary

MeasureTime frame
The main study parameter is fasting levels of plasma glucose.

Secondary

MeasureTime frame
-

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)